Targeting the ERβ/HER Oncogenic Network in
Animals
CD8-Positive T-Lymphocytes
/ drug effects
Carcinogenesis
/ genetics
Cell Line, Tumor
Estrogen Receptor beta
/ genetics
Female
Humans
Immunotherapy
/ methods
Lung Neoplasms
/ genetics
Lymphocytes, Tumor-Infiltrating
/ drug effects
Macrophages
/ drug effects
Mice
Oncogenes
/ genetics
Programmed Cell Death 1 Receptor
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Quinazolinones
/ pharmacology
Receptor, ErbB-2
/ genetics
Tumor Microenvironment
/ genetics
ER
HER
KRAS
NSCLC
PAM50
TME
anti-PD-1
immunotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Dec 2021
22 Dec 2021
Historique:
received:
29
09
2021
revised:
13
12
2021
accepted:
20
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
1
2
2022
Statut:
epublish
Résumé
High ERβ/HER oncogenic signaling defines lung tumors with an aggressive biology. We previously showed that combining the anti-estrogen fulvestrant with the pan-HER inhibitor dacomitinib reduced ER/HER crosstalk and produced synergistic anti-tumor effects in immunocompromised lung cancer models, including
Identifiants
pubmed: 35008514
pii: ijms23010081
doi: 10.3390/ijms23010081
pmc: PMC8745184
pii:
doi:
Substances chimiques
Estrogen Receptor beta
0
KRAS protein, human
0
Programmed Cell Death 1 Receptor
0
Quinazolinones
0
dacomitinib
5092U85G58
Receptor, ErbB-2
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Minnesota Foundation through a donation from the State of Minnesota Eagles of the Masonic Cancer Center
ID : no grant number
Organisme : Alice and Frederick Stark Endowed Chair in Pharmacology
ID : no grant number
Organisme : A Breath of Hope Lung Foundation Tona Vives Award
ID : no grant number
Organisme : Hillman Fellows for Innovative Cancer Research Program
ID : no grant number
Organisme : Imam Abdulrahman Bin Faiscal University fellowship program in conjunction with the Saudi Arabian Cultural Mission (SACM) to the USA
ID : no grant number
Références
Transl Lung Cancer Res. 2019 Oct;8(5):710-714
pubmed: 31737508
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Mol Cell Biol. 1998 Jul;18(7):4209-20
pubmed: 9632805
Br J Cancer. 2021 Jan;124(2):383-390
pubmed: 33012782
Methods Mol Biol. 2019;1960:93-99
pubmed: 30798524
Cancer Res. 2007 Dec 15;67(24):11924-32
pubmed: 18089823
Oncoimmunology. 2017 Jul 26;6(11):e1356145
pubmed: 29147605
Clin Cancer Res. 2020 Apr 15;26(8):2037-2046
pubmed: 31937613
Lung Cancer. 2018 Sep;123:91-98
pubmed: 30089602
Clin Cancer Res. 2016 Dec 15;22(24):6204-6216
pubmed: 27267852
Int J Mol Sci. 2019 Oct 05;20(19):
pubmed: 31590386
Immunotherapy. 2013 Oct;5(10):1075-87
pubmed: 24088077
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
Trends Pharmacol Sci. 2014 Aug;35(8):414-22
pubmed: 24975478
J Immunother Cancer. 2019 Jul 10;7(1):172
pubmed: 31291990
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Oncologist. 2021 Apr;26(4):290-e545
pubmed: 33296125
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270272
Cancer Cell. 2021 Oct 11;39(10):1375-1387.e6
pubmed: 34416167
Ther Adv Med Oncol. 2018 Jan 09;10:1758834017745012
pubmed: 29383034
J Thorac Oncol. 2020 Jan;15(1):62-79
pubmed: 31606604
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
Drugs. 2020 Jun;80(9):883-892
pubmed: 32436070
Lung Cancer. 2009 Apr;64(1):51-9
pubmed: 18701186
Front Immunol. 2019 Jul 19;10:1719
pubmed: 31379886
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33351788
Ann Oncol. 2020 Apr;31(4):507-516
pubmed: 32139298
Clin Cancer Res. 2009 May 15;15(10):3396-405
pubmed: 19451593
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Hematol Oncol. 2017 Jul 28;10(1):145
pubmed: 28754125
Sci Transl Med. 2018 Jun 20;10(446):
pubmed: 29925635
Sci Rep. 2015 Nov 05;5:16280
pubmed: 26538233
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Target Oncol. 2019 Aug;14(4):417-421
pubmed: 31346927
Clin Cancer Res. 2016 Apr 15;22(8):1856-64
pubmed: 27084739
Mediators Inflamm. 2014;2014:270302
pubmed: 25045209
Br J Cancer. 2020 Apr;122(8):1166-1174
pubmed: 32147669
Clin Cancer Res. 2015 Aug 15;21(16):3794-805
pubmed: 25901081
Sci Transl Med. 2018 Jun 20;10(446):
pubmed: 29925636
Neoplasia. 2015 Nov;17(11):817-25
pubmed: 26678909
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Cancer Chemother Pharmacol. 2020 May;85(5):917-930
pubmed: 32274564
BMC Cancer. 2016 Jul 11;16:440
pubmed: 27400708
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Immunol. 2015 May 1;194(9):4545-54
pubmed: 25810391